Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8199080 | 0.89 | CYP26A1 (0.49) | SIGMAR1CYP26A1DGAT1HRH3SLC18A3 | |
| SCHEMBL6492064 | 0.86 | SIGMAR1 (0.70) | SIGMAR1HTR1AACHEHTR2ADRD2 | |
| SCHEMBL6502513 | 0.84 | SIGMAR1 (0.54) | SIGMAR1HTR1ACYP26A1ACHESLC18A3 | |
| SCHEMBL6491622 | 0.84 | SIGMAR1 (0.50) | SIGMAR1HTR1ACYP26A1HTR2ADRD2 | |
| SCHEMBL6502043 | 0.84 | CYP24A1 (0.60) | SIGMAR1HTR1ACYP26A1HTR2ADRD2 | |
| SCHEMBL6491492 | 0.81 | ADRA1D (0.54) | SIGMAR1HTR1ACYP26A1HRH3HTR2A | |
| SCHEMBL6503237 | 0.79 | SIGMAR1 (0.51) | SIGMAR1HTR1ACCR5HTR2ADRD2 | |
| SCHEMBL8200537 | 0.77 | ADRA1D (0.56) | SIGMAR1CYP26A1ACHEHTR2ADRD2 | |
| SCHEMBL8199307 | 0.76 | CYP26A1 (0.55) | SIGMAR1CYP26A1SLC18A3DRD2 | |
| SCHEMBL8200296 | 0.75 | ADRA1D (0.50) | SIGMAR1CYP26A1ACHEHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998036749-A1 | TETRALONE DERIVATIVES AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | SIGMAR1 50/4885HTR1A 476/4885CYP26A1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.